Compare ALPS & JHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ALPS | JHS |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Finance Companies |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.4M | 127.9M |
| IPO Year | N/A | 1994 |
| Metric | ALPS | JHS |
|---|---|---|
| Price | $0.68 | $11.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 24.0K | 17.2K |
| Earning Date | 07-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $10.74 |
| 52 Week High | $1.72 | $12.09 |
| Indicator | ALPS | JHS |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 55.40 |
| Support Level | $0.64 | $11.02 |
| Resistance Level | $1.11 | $11.28 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 22.32 | 95.65 |
ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.
John Hancock Income Securities Trust is a United States-based closed-end diversified management investment company. Its main objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.